Lumpy skin disease vaccine developed by Bharat Biotech group firm with ICAR gets CDSCO licence

Lumpy skin disease vaccine developed by Bharat Biotech group firm with ICAR gets CDSCO licence

Daily Current Affairs   /   Lumpy skin disease vaccine developed by Bharat Biotech group firm with ICAR gets CDSCO licence

Change Language English Hindi

Category : Science and Tech Published on: February 17 2025

Share on facebook
  • Biovet, a Bharat Biotech group firm, received CDSCO approval for Biolumpivaxin, the world's first DIVA marker vaccine for lumpy skin disease (LSD) in cattle and buffaloes, developed in collaboration with ICAR.
  • This vaccine received approval from the Central Drugs Standard Control Organization (CDSCO) for commercial use.
Recent Post's
  • Exercise Tiger Triumph 2024, a Tri-Service India-US Humanitarian Assistance and Disaster Relief (HADR) exercise, began in Visakhapatnam on April 1, 2025.

    Read More....
  • Shirley Botchwey becomes the first African woman to assume office as Commonwealth Secretary-General.

    Read More....
  • Indian hockey icon Vandana Katariya announces her retirement after an illustrious 15-year career.

    Read More....
  • The Hero Asia Cup Hockey 2025 will be held in Rajgir, Bihar from August 29 to September 7, at the newly constructed Rajgir Hockey Stadium.

    Read More....
  • The 6th BIMSTEC Summit will convene in Bangkok on April 4, focusing on trade, security, and regional cooperation.

    Read More....
  • The Punjab government plans to develop the Jhajjar-Bachauli Wildlife Sanctuary as the state's first leopard safari destination.

    Read More....
  • The Telangana government launches its first free fine rice scheme through ration shops.

    Read More....
  • Miami Open Champion: Teenager Jacob Menchi defeated Novak Djokovic in the finals.

    Read More....
  • The Indian Air Force will participate in the multinational air exercise INIOCHOS-25 in Greece.

    Read More....
  • SpaceX launches a private astronaut crew in the Fram2 polar-orbiting mission.

    Read More....